NCT05195034

Effect of Dexmedetomidine on Postoperative Delirium After Awake Craniotomies

Effect of Dexmedetomidine on Postoperative Delirium in Patients Undergoing Awake Craniotomies: a Randomized Controlled Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 210 (estimated)
• Sponsor: Beijing Tiantan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Postoperative delirium (POD) is a common complication, and the incidence of POD ranges from 10% to 60%. Previous studies suggested that frontal approach and tumor located at the temporal lobe were independent risk factors for POD after supratentorial tumor resections. Therefore, patients undergoing awake craniotomies are high-risk populations for POD. A lot of trials show that dexmedetomidine might help to reduce the incidence of delirium in patients undergoing non-cardiac surgery. However, the impact of dexmedetomidine (DEX) on POD for patients undergoing awake craniotomies remains unclear. The purpose of this study was to investigate the effect of DEX on POD in patients undergoing awake craniotomies.

Conditions

• Dexmedetomidine
• Delirium
• Awake Craniotomy

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
DRUG	0.9% saline	The 0.9% saline is administered with the same volume at the same speed as the other group.

Timeline

• Start date: 2022-03-31
• Primary completion: 2025-11-30
• Completion: 2025-12-31
• First posted: 2022-01-18
• Last updated: 2025-02-13

Locations

1 site across 1 country: China